button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive

versus docetaxel
atezolizumab alone vs. docetaxel 1 certainty unassessablestatistically conclusive-21% certainty unassessable-12%-
avelumab alone vs. docetaxel 1 certainty unassessable-9% certainty unassessable+1%-
pembrolizumab (10mg/kg) vs. docetaxel 2 low degree of certaintystatistically conclusive-39% low degree of certaintystatistically conclusive-28%-
pembrolizumab (2mg/kg) vs. docetaxel 2 low degree of certaintystatistically conclusive-33% low degree of certainty-25%-
versus Standard of Care (SoC)
durvalumab alone vs. Standard of Care (SoC) 1 certainty unassessable-34% certainty unassessable-27%-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons